Valuation: Ipsen

Market Cap 11.89B 13.31B 11.09B 10.07B 18.97B 1,287B 19.12B 133B 52.07B 655B 49.95B 48.87B 2,104B P/E 2026 *
12.1x
P/E 2027 * 12.2x
Enterprise Value 10.63B 11.9B 9.92B 9.01B 16.96B 1,151B 17.09B 119B 46.55B 585B 44.66B 43.69B 1,881B EV / Sales 2026 *
2.32x
EV / Sales 2027 * 2.05x
Free-Float
40.65%
Yield 2026 *
1.06%
Yield 2027 * 1.06%
1 day-1.10%
1 week+1.99%
Current month+0.91%
1 month-9.92%
3 months-13.61%
6 months-12.08%
Current year+20.50%
1 week 138.3
Extreme 138.3
145
1 month 138.3
Extreme 138.3
161.4
Current year 116
Extreme 116
174
1 year 112.7
Extreme 112.7
174
3 years 87.95
Extreme 87.95
174
5 years 77
Extreme 77
174
10 years 34.2
Extreme 34.2
174
Manager TitleAgeSince
Chief Executive Officer 59 01/07/2020
Chief Executive Officer 57 01/01/2020
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 61 30/08/2005
Chairman 68 22/11/2010
Director/Board Member 69 01/06/2012
Date Insider Type Main position Quantity % Market Cap. Importance
9/21/26 A Buy

Director

500 0.0006%
9/8/26 A Buy

Director

500 0.0006%
9/3/26 A Sell

Director

-1,000 0.0012%
Change 5-day change 1-year change 3-year change Capi.($)
-1.10%+1.99%+22.35%+19.00% 13.31B
-1.84%+2.73%+40.91%+110.31% 1,060B
-0.68%-2.38%+36.83%+63.95% 623B
-0.59%+3.73%+16.55%+83.05% 480B
-1.01%-1.73%+62.98%+37.46% 352B
-1.11%+2.18%+22.42%+42.16% 345B
-1.07%+1.02%+11.98%+35.32% 274B
-1.08%-1.48%-5.34%+11.44% 249B
-1.25%-2.00%+39.77%+54.44% 223B
-0.52%-1.48%+25.75%+96.48% 182B
Average -1.03%-0.23%+27.42%+55.36% 380.13B
Weighted average by Cap. -1.13%+0.04%+31.56%+70.18%

Financials

2026 *2027 *
Net sales 4.59B 5.14B 4.28B 3.89B 7.33B 497B 7.38B 51.46B 20.11B 253B 19.29B 18.87B 813B 4.69B 5.25B 4.37B 3.97B 7.48B 507B 7.54B 52.55B 20.53B 258B 19.69B 19.27B 830B
Net income 1.01B 1.13B 944M 857M 1.61B 110B 1.63B 11.34B 4.43B 55.7B 4.25B 4.16B 179B 1B 1.12B 935M 849M 1.6B 108B 1.61B 11.23B 4.39B 55.16B 4.21B 4.12B 177B
Net Debt -1.26B -1.41B -1.18B -1.07B -2.01B -136B -2.03B -14.13B -5.52B -69.39B -5.3B -5.18B -223B -2.28B -2.55B -2.12B -1.93B -3.63B -246B -3.66B -25.51B -9.97B -125B -9.56B -9.35B -403B
Projected Income Statement - Annual - Ipsen
Logo Ipsen
Ipsen specialises in the research, development, manufacture and marketing of specialty medicines. Net sales by therapeutic area break down as follows: - oncology (69.2%); - neuroscience (20.3%); - rare diseases (10.5%). At the end of 2025, the group had 7 research and development centers located in France (2), the United Kingdom (2), China (2) and Ireland, and 5 manufacturing sites worldwide. Net sales are distributed geographically as follows: France (8%), Europe (31.7%), the United States (32.9%), North America (2.2%) and other (25.2%).
Employees
5,535
Date Price Change Volume
08/10/26 €143.40 -1.10% 13,259
07/10/26 €145.00 +3.13% 118,786
06/10/26 €140.60 0.00% 160,930
05/10/26 €140.60 +0.72% 71,989
02/10/26 €139.60 -0.71% 97,499
Trader
Investor
Global
Quality
ESG MSCI
AA
Ratings Surperformance© - Ipsen
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
145.00EUR
Average target price
164.73EUR
Spread / Average Target
+13.61%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Ipsen